

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

RL

RRID:CVCL_1660

Type: Cell Line

Proper Citation

RRID:CVCL_1660

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1660

Proper Citation: RRID:CVCL_1660

Description: Cell line RL is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma

Defining Citation: [PMID:2313723](#), [PMID:16960149](#), [PMID:17363600](#), [PMID:17495976](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23292937](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RL

Cross References: BTO:BTO_0003230, CLO:CLO_0008828, EFO:EFO_0002319, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2261, BioSample:SAMN01821593, BioSample:SAMN01821659, BioSample:SAMN03471851, BioSample:SAMN03472493, BioSample:SAMN10988269, cancercellines:CVCL_1660, Cell_Model_Passport:SIDM01089, ChEMBL-Cells:ChEMBL3308515, ChEMBL-

Targets:CHEMBL2366175, Cosmic:910861, Cosmic:1945189, Cosmic:2022593, Cosmic:2297011, Cosmic-CLP:910861, DepMap:ACH-000371, DSMZ:ACC-613, DSMZCellDive:ACC-613, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:910861, GEO:GSM115984, GEO:GSM179647, GEO:GSM887543, GEO:GSM888626, GEO:GSM1035303, GEO:GSM1105702, GEO:GSM1670381, IARC_TP53:21288, IARC_TP53:25030, IGRhCellID:RL, LiGeA:CCLE_654, LINCS_LDP:LCL-1133, Lonza:1366, PharmacDB:RL_1318_2019, PRIDE:PXD030304, Progenetix:CVCL_1660, PubChem_Cell_line:CVCL_1660, Wikidata:Q54950574

ID: CVCL_1660

Record Creation Time: 20220427T221500+0000

Record Last Update: 20260829T235740+0000

Ratings and Alerts

No rating or validation information has been found for RL.

No alerts have been found for RL.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. *iScience*, 25(3), 103985.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Menzl I, et al. (2019) A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. *Nature communications*, 10(1), 4741.

Liang K, et al. (2017) Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. *Cell*, 168(1-2), 59.